6/29/26
SUPERNUS PHARMACEUTICALS (SUPN) Thesis: Recent clinical trial results for competitors have raised concerns about Supernus's market position, leading to a reassessment of growth expectations.
★ Analysts see FY2026 revenue reaching $867M — +20.6% growth in a single year.
What Moves the Stock 1 FDA approval of new drugs in the pipeline, particularly for CNS disorders 2 Changes in prescription trends for existing products 3 Market share gains in the ADHD and epilepsy segments 4 Partnerships or collaborations with larger pharmaceutical firms 5 Product sales from epilepsy treatments (estimated 70% of total revenue) 6 Product sales from ADHD treatments (estimated 30% of total revenue) 7 Increased focus on mental health treatments 8 Advancements in drug delivery systems 41.6 46.3 51 56 61 46.84 SUPN Daily 46.84 Feb '26 Mar '26 May '26 Jun '26
My Notes "Management noted, 'We are facing increased competition that could impact our growth trajectory in the near term.'" Moat: Supernus's focus on niche CNS disorders provides a degree of protection against larger competitors. growth - Investors are likely drawn to the potential for revenue growth from new product launches and market expansion. Minimal impact as the company has low debt levels, but rising rates could affect valuation multiples. Watch on earnings: FDA approval timelines for SPN-812 and other pipeline drugs, Market share in ADHD and epilepsy treatments, Gross margin trends. One Sentence Summary: Supernus Pharmaceuticals: the story is balanced — fda approval of new drugs in the pipeline, particularly for cns disorders.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.